Rifaximin - Chitosan Nanoparticles for Inflammatory Bowel Disease ( IBD).

CONCLUSION: Nanoparticles with small particle size found to have high encapsulation efficiency and relatively high loading capacity and predetermined in vitro release profile.
PMID: 28034350 [PubMed - as supplied by publisher]

Source: Recent Patents on Inflammation and Allergy Drug Discovery - January 1, 2017 Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research